Ultimately, TP53, PRKDC, BRCA2, BRCA1, and ATM mutations may be potential biomarkers for predicting the clinical response of patients to immunotherapy to improve breast cancer survival. This evidence concerns the gene BRCA2 and breast carcinoma.